Stock Comparison
JNJ vs PFE vs MRK
Side-by-side fundamentals, quality, value, and price momentum analysis.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Metrics Comparison
Best values highlighted in green, worst in red. Scroll horizontally to see all tickers.
| Metric | JNJJohnson & Johnson | PFEPfizer Inc. | MRKMerck & Co., Inc. |
|---|---|---|---|
| Market Cap | $514.75B | $143B | $268.7B |
| Current Price | $213.65 | $25.15 | $108.26 |
| P/E Ratio | 36.90 | 17.84 | 16.06 |
| Revenue Growth 1Y | 4.3% | 6.8% | 6.7% |
| Net Margin | 15.8% | 12.6% | 26.7% |
| ROE | 20.1% | 9% | 40.8% |
| ROIC | 20.6% | 7.9% | 21.9% |
| Debt/Equity | 0.53 | 0.76 | 0.83 |
| FCF Yield | 3.9% | 6.9% | 6.7% |
| Dividend Yield | 2.3% | 6.6% | 2.9% |
JNJ vs PFE vs MRK: Key Questions Answered
Which is the cheapest stock: JNJ, PFE, MRK?
Based on P/E ratio, Merck & Co., Inc. (MRK) is the cheapest at 16.1x earnings. Johnson & Johnson (JNJ) is the most expensive at 36.9x. A lower P/E can indicate better value, but always consider growth rates too.
Which stock is growing the fastest: JNJ, PFE, MRK?
Pfizer Inc. (PFE) is growing the fastest with 6.8% revenue growth. Johnson & Johnson has the slowest growth at 4.3%. Higher growth often justifies higher valuations.
Which has the best profit margins: JNJ, PFE, MRK?
Merck & Co., Inc. (MRK) has the strongest profitability with a 26.7% net margin. Pfizer Inc. has the lowest at 12.6%. Higher margins indicate pricing power and efficiency.
Which pays the highest dividend: JNJ, PFE, MRK?
Pfizer Inc. (PFE) offers the highest dividend yield of 6.6%. Johnson & Johnson has the lowest at 2.3%. For income investors, higher yield matters, but check payout sustainability.
Which is the largest company: JNJ, PFE, MRK?
Johnson & Johnson (JNJ) is the largest company with a market cap of $514.7B. Pfizer Inc. is the smallest at $143.0B. Larger companies tend to be more stable but may have less growth potential.
Which stock has the best return on equity: JNJ, PFE, MRK?
Merck & Co., Inc. (MRK) generates the best returns on shareholder equity with an ROE of 40.8%. Pfizer Inc. has the lowest at 9.0%. Higher ROE indicates efficient use of capital.